Model-Based Meta-Analysis (MBMA) Archives

Blog

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…

CertaraDecember 15, 2021

Blog

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…

CertaraDecember 19, 2019

Publication

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…

CertaraJune 2, 2018

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

CertaraFebruary 15, 2018

White Paper

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

CertaraAugust 24, 2017

White Paper

Model-based Meta-analysis: An Innovative Methodology Comes of Age

MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions.…

CertaraJuly 14, 2016

Publication

Short-term Efficacy Reliably Predicts Long-term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-based Meta-analysis

The objective of this study was to assess the relationship between short-term and long-term treatment…

CertaraJuly 1, 2016

Publication

Does Age Affect Gastric Emptying Time? A Model-based Meta-analysis

Gastric emptying (GE) is often reported to be slower and more irregular in premature neonates than…

CertaraMay 1, 2015

Publication

A Model-based Dose-response Meta-analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma

PURPOSE: To characterize dose and response for intraocular pressure (IOP) reduction and incidence of hyperemia…

CertaraMay 1, 2015

Publication

Time Course of Bone Mineral Density Changes with Denosumab Compared with Other Drugs in Postmenopausal Osteoporosis: A Dose-response-based Meta-analysis

Our objective was to compare the time course of bone mineral density (BMD) changes at…

CertaraOctober 1, 2014

Model-Based Meta-Analysis (MBMA)

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Model-based Meta-analysis: An Innovative Methodology Comes of Age

Short-term Efficacy Reliably Predicts Long-term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-based Meta-analysis

Does Age Affect Gastric Emptying Time? A Model-based Meta-analysis

A Model-based Dose-response Meta-analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma

Time Course of Bone Mineral Density Changes with Denosumab Compared with Other Drugs in Postmenopausal Osteoporosis: A Dose-response-based Meta-analysis

Newsletter sign up

Quick links

Solutions

Contact